1.Interleukin-1 progesterone and estradiol levels of amnoitic fluids in the term pregnant women.
Korean Journal of Obstetrics and Gynecology 1993;36(2):173-183
No abstract available.
Estradiol*
;
Female
;
Humans
;
Interleukin-1*
;
Pregnant Women*
;
Progesterone*
2.A Case of Recurrent Bacterial Meningitis with CSF Rhinorrhea.
Dae Shik KIM ; Jin Yong LEE ; Chang Jun COE ; Jin Suk SUH
Journal of the Korean Pediatric Society 1989;32(8):1161-1166
No abstract available.
Meningitis, Bacterial*
3.A case of successful treatment of cervical pregnancy with methotrexate.
Do Young HWANG ; Jin CHOE ; Sang Duk SHIM ; Dae Shik SUH ; Young Min CHOI ; Syng Wook KIM
Korean Journal of Obstetrics and Gynecology 1992;35(3):429-436
No abstract available.
Methotrexate*
;
Pregnancy*
4.Outcomes and prognostic factors of surgically treated extramammary Paget’s disease of the vulva
Angela CHO ; Dae-Yeon KIM ; Dae-Shik SUH ; Jong-Hyeok KIM ; Yong-Man KIM ; Young-Tak KIM ; Jeong-Yeol PARK
Journal of Gynecologic Oncology 2023;34(6):e76-
Objective:
Extramammary Paget’s disease (EMPD) of the vulva is a rare disease which predominantly presents in postmenopausal Caucasian women. As yet, no studies on Asian female patients with EMPD have been performed. This study aimed to identify the clinical features of patients with vulvar EMPD in Korea, and to evaluate the risk factors of recurrence and postoperative complications in surgically treated EMPD.
Methods:
We retrospectively reviewed 47 patients with vulvar EMPD who underwent wide local excision or radical vulvectomy. The clinical data and surgical and oncological outcomes following surgery were extracted from medical records and analyzed. Univariate and multivariate analyses for predicting recurrence and postoperative complications were performed.
Results:
21.3% of patients had complications after surgery, and wound dehiscence was the most common. 14.9% of patients experienced recurrence, and the median interval to recurrence from initial treatment was 69 (range 33–169) months. Vulvar lesions larger than 40 mm was the independent risk factor of postoperative complications (odds ratio [OR]=7.259; 95% confidence interval [CI]=1.545–34.100; p=0.012). Surgical margin status was not associated with recurrence in surgically treated vulvar EMPD patients (OR=0.83; 95% CI=0.16–4.19; p=1.000).
Conclusion
Positive surgical margin is a frequent finding in the patients with vulvar EMPD, but disease recurrence is not related with surgical margin status. Since EMPD is a slow growing tumor, a surveillance period longer than 5 years is required.
5.Primary Central Nervous System Lymphomas; A Clinicopathologic Study of 18 Cases.
Yu Kyung JEONG ; Young Hyeh KO ; Dong Kyu NA ; Yeon Lim SUH ; Sang Yong SONG ; Dae Shik KIM ; Mi Kyung KIM ; Howe Jung REE
Korean Journal of Pathology 1998;32(9):670-679
The incidence of a primary central nervous system (CNS) lymphoma in western countries is about 1% of all the intracranial tumors and has increased 2.2% over the last decade. A similar pattern of increased frequency is observed in Korea. Although most CNS lymphomas in western countries are high grade tumors carrying poor prognosis, the clinicopathologic features of the Korean CNS lymphoma have not been well studied. We report clinicopathological features of 18 cases of histologically proven primary brain lymphoma. The mean age of the patients was 50 years and there was no sex difference. The clinical and radiological characteristics included multiple site of occurrence, infrequent extracranial spread, and frequent seeding via cerebrospinal fluid. No patients were immune-compromised host. Of 18 cases, 15 cases were of B-lineage and 2 cases were of T-lineage. According to REAL classification, there were 12 cases of diffuse large B cell lymphoma, two cases of B cell lymphomas of small lymphoid cell, and two cases of peripheral T cell lymphoma, unspecified. The remaining subtypes were not subclassified because of inadequate material. Pleomorphic cytologic features and necrosis of varying extent were frequent in the cases of diffuse large B-cell lymphoma. These results suggest that overall clinicopathologic features of primary malignant lymphomas of the central nervous system in Korea are similar to those of western countries.
Brain
;
Central Nervous System*
;
Cerebrospinal Fluid
;
Classification
;
Humans
;
Incidence
;
Korea
;
Lymphocytes
;
Lymphoma*
;
Lymphoma, B-Cell
;
Lymphoma, T-Cell, Peripheral
;
Necrosis
;
Prognosis
;
Sex Characteristics
6.Treatment efficacy of high dose progestin in young women with early stage of endometrial carcinoma.
Yun Hyun CHO ; Dae Shik SUH ; Yong Il JI ; Dae Yeon KIM ; Jong Hyeok KIM ; Yong Man KIM ; Young Tak KIM ; Joo Hyun NAM
Korean Journal of Obstetrics and Gynecology 2007;50(3):486-493
OBJECTIVE: The aim of this study is to investigate the effectiveness of high dose progestins in young patients with early stage of endometrial cancer. METHODS: Between April 1998 and December 2005, 10 women with early stage of endometrial carcinoma were treated with high dose progestins as primary therapy for the purpose of saving fertility. RESULTS: They took 80~160 mg of megestrol acetate or 500~1,000 mg of medroxyprogesterone acetate per day, and then followed up with the endometrial curettages. Seven patients (70.0%) responded to the treatment. Three patients didn't respond and so underwent hysterectomy as definite treatment. Four patients were able to become pregnant after completing treatment. No patients died of their disease. CONCLUSION: The majority of patients with well-differentiated endometrial adenocarcinoma who underwent conservative treatment with a progestational agent responded to the treatment. High-dose progestin therapy can be used as primary therapy in selected young women with early stage of endometrial carcinoma.
Adenocarcinoma
;
Curettage
;
Endometrial Neoplasms*
;
Female
;
Fertility
;
Humans
;
Hysterectomy
;
Medroxyprogesterone Acetate
;
Megestrol Acetate
;
Progestins
;
Treatment Outcome*
7.Erratum: Author correction.
Young Jae LEE ; Yong Man KIM ; Hyun Jin KIM ; Sung Wook CHOI ; Shin Wha LEE ; Jeong Yeol PARK ; Dae Yeon KIM ; Dae Shik SUH ; Jong Hyeok KIM ; Young Tak KIM ; Joo Hyun NAM
Obstetrics & Gynecology Science 2017;60(6):621-621
The Editorial Office of Obstet Gynecol Sci would like to correct the author list.
8.Laparoendoscopic single-site versus conventional laparoscopic surgery for ovarian mature cystic teratoma.
Jeong Yeol PARK ; Dae Yeon KIM ; Dae Shik SUH ; Jong Hyeok KIM ; Joo Hyun NAM
Obstetrics & Gynecology Science 2015;58(4):294-301
OBJECTIVE: To compare the intraoperative and postoperative outcomes of laparoendoscopic single-site surgery (LESS) versus conventional laparoscopic surgery in women with ovarian mature cystic teratoma. METHODS: A retrospective review of 303 women who underwent LESS (n=139) or conventional laparoscopic surgery (n=164) due to ovarian mature cystic teratoma was performed. Intra- and postoperative outcomes were compared between the two groups. RESULTS: There was no intergroup difference in age, body weight, height, body mass index, comorbidities, tumor size, bilaterality of tumor, or the type of surgery. However, more patients in the LESS group had a history of previous abdominal surgery (19.4% vs. 6.7%, P=0.001). Surgical outcomes including operating time (89 vs. 87.8 minutes, P=0.734), estimated blood loss (69.4 vs. 68.4 mL, P=0.842), transfusion requirement (2.2% vs. 0.6%, P=0.336), perioperative hemoglobin level change (1.3 vs. 1.2 g/dL, P=0.593), postoperative hospital stay (2.0 vs. 2.1 days, P=0.119), and complication rate (1.4% vs. 1.8%, P=0.999) did not differ between LESS and conventional groups. Postoperative pain scores measured using a visual analogue scale were significantly lower in the LESS group at 8 hours (P=0.021), 16 hours (P=0.034), and 32 hours (P=0.004) after surgery, and 32 of 139 patients (23%) in the LESS group and 78 of 164 patients (47.6%) in the conventional group required at least one additional analgesic (P<0.001). CONCLUSION: LESS was feasible and showed comparable surgical outcomes with conventional laparoscopic surgery for women with ovarian mature cystic teratoma. LESS was associated with less postoperative pain and required less analgesia.
Analgesia
;
Body Height
;
Body Weight
;
Comorbidity
;
Female
;
Humans
;
Laparoscopes
;
Laparoscopy*
;
Length of Stay
;
Ovary
;
Pain, Postoperative
;
Retrospective Studies
;
Teratoma*
9.Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy.
Yong Soon KWON ; Joo Hyun NAM ; Dae Yeon KIM ; Dae Shik SUH ; Jong Hyeok KIM ; Yong Man KIM ; Young Tak KIM
Journal of Korean Medical Science 2009;24(4):679-683
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.
Altretamine/*therapeutic use
;
Antineoplastic Agents, Alkylating/*therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Disease-Free Survival
;
Female
;
Humans
;
Middle Aged
;
Neoplasm Staging
;
Neoplasms, Glandular and Epithelial/*drug therapy/mortality
;
Ovarian Neoplasms/*drug therapy/mortality
;
Retrospective Studies
10.Effectiveness and safety of oral capecitabine in patients with gynecologic cancers.
Hang Jo YOU ; Yong Man KIM ; Shin Wha LEE ; Dae Yeon KIM ; Dae Shik SUH ; Jong Hyeok KIM ; Young Tak KIM ; Joo Hyun NAM ; Jung Eun MOK
Korean Journal of Gynecologic Oncology 2007;18(4):333-340
OBJECTIVE: To determine the efficacy and safety of capecitabine in patients with gynecologic cancers as adjuvant chemotherapy or maintenance treatment. METHODS: In this study, patients who were treated with capecitabine between January 2000 and June 2007 at Asan Medical Center, Seoul, Korea were reviewed. Thirty-one patients with gynecologic cancers were included 16 patients with recurrent ovarian cancer, 9 patients with cervical cancer after initial treatment, and 6 patients with recurrent cervical cancer. These patients' data were analyzed by review of medical records and pathologic and laboratory reports retrospectively. Response was assessed by both RECIST criteria for patients with measurable disease and CA 125 criteria in patients with ovarian cancer and National Cancer Institute criteria for progression, response, and toxicity were utilized in cervical cancer. RESULTS: Capcitabine was given at a dosage of 2,000-2,500 mg/m2/day orally in a divided dose daily for 14 days followed by a 7-day rest period in all patients. Nine patients with ovarian cancer were treated with more than 2 cycles and their median age was 49 years (43-67). Two patients showed a partial response and the median progression free survival was 3 months. Nine patients with cervical cancer after initial treatment were in the complete response state and their median progression free survival was 24.5 months. No partial or complete responses were seen in 6 patients with recurrent cervical cancer. There was no severe toxicity. CONCLUSION: Although capecitabine is a well-tolerated regimen, as a single agent, it produces minimal benefit in recurrent ovarian and cervical cancer population.
Chemotherapy, Adjuvant
;
Chungcheongnam-do
;
Disease-Free Survival
;
Humans
;
Korea
;
Medical Records
;
National Cancer Institute (U.S.)
;
Ovarian Neoplasms
;
Retrospective Studies
;
Seoul
;
Uterine Cervical Neoplasms
;
Capecitabine